Introduction
============

Prospective randomized trials have demonstrated an improvement in biochemical progression-free survival [@b1]--[@b3], distant metastasis-free survival [@b4], and overall survival [@b4] with the addition of adjuvant radiation therapy (RT) to the prostate fossa after radical prostatectomy (RP) for men with high-risk pathological features (positive surgical margins, extracapsular extension, and/or seminal vesicle invasion). However, many clinicians prefer delayed salvage RT for patients selected based upon prostate serum antigen (PSA)-defined recurrence, rather than immediate treatment, due to concerns about overtreatment and complications with adjuvant radiation therapy (ART), as well as published evidence that supports the effectiveness of salvage RT [@b5],[@b6]. Retrospective data have demonstrated that salvage RT for PSA failure after RP improves prostate cancer-specific mortality [@b7].

The prostate bed is the most common site of failure after RP [@b8], and the volume targeted by postprostatectomy RT encompasses the prostate bed, including the vesicourethral anastomosis and seminal vesicle remnant along with added margin for setup error [@b9]. As the prostate bed target volume is adjacent to normal tissue structures, including bladder and rectum, advanced delivery approaches have been investigated. Dosimetric comparisons of intensity-modulated RT (IMRT) to conformal RT (CRT) techniques have shown that IMRT treatment planning reduces the volume of bladder and rectum exposed to high RT doses and allows for dose escalation to the target volume without exceeding bladder and rectum constraints [@b10],[@b11].

IMRT has been adopted widely in the United States, with nearly 90% of radiation oncologists reporting the use of IMRT for postprostatectomy treatment [@b6], consistent with an overall trend of increasing use of IMRT for prostate cancer over the past decade [@b12]. However, there is scant clinical evidence to show that the dosimetric superiority of IMRT over CRT translates into more effective treatments for prostate cancer patients, and IMRT has not been compared to CRT in randomized controlled trials. Some small studies have provided encouraging early clinical results of postprostatectomy IMRT [@b13],[@b14], but the increased expense of IMRT over CRT [@b10],[@b12] warrants more and high-quality data to evaluate the comparative effectiveness of these techniques in this setting.

In this report, we evaluate the comparative effectiveness of IMRT versus CRT for adjuvant and salvage RT after RP among a cohort of elderly patients who qualified for ART based upon the presence of adverse pathological features in the surgical specimen. As the rationale for IMRT over CRT is primarily the reduced risk of complications through improved normal tissue sparing from high RT doses [@b15],[@b16], we compared the incidence of genitourinary (GU), gastrointestinal (GI), and sexual complications between these two techniques.

Methods and Materials
=====================

Study design
------------

This was an observational cohort study of complications after IMRT or CRT using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, a research resource that links the SEER tumor registry with Medicare administrative claims [@b17]. From among the 523,153 prostate cancer cases recorded in the SEER registry during 1992--2008, we identified patients who received RP, had one or more adverse pathologic feature (seminal vesicle invasion, extracapsular extension, positive surgical margins), and who received postoperative RT between the years of 1995 and 2007. To increase the accuracy of measured health claims, only men aged 66 years or older at time of diagnosis were included to ensure that 1 year of data were available prior to diagnosis; men who were also enrolled in a health maintenance organization during the study were excluded; and men who were not continually enrolled in both Medicare Parts A and B starting 1 year prior to diagnosis were excluded. Additional exclusion criteria included involved lymph nodes, treatment with brachytherapy, and treatment with proton beam therapy (Fig. S1). Based upon the SEER data variables, a cohort of 6345 subjects was identified, and subsequent exclusions were based upon Medicare data elements. Delivered treatments (RP, IMRT, CRT) were identified based upon Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), and associated International Classification of Diseases (ICD) codes (Table S1). These administrative claims codes were adapted based upon review of several prior published reports [@b15],[@b16],[@b18],[@b19]. The final cohort comprised only men who met eligibility criteria for ART after RP, and included 1052 subjects who received CRT and 634 subjects who received IMRT after RP (Fig. S1).

Study variables
---------------

Rates of first complication events occurring 1 year or more after start of RT were compared between the treatment groups. First complication events were defined based upon HCPCS/CPT-4 procedure codes and ICD-9 diagnosis codes (Table S1). Complication events for analysis were limited to those occurring 1 year or more after start of RT as the focus of this study was a comparison of late treatment-related toxicity. The primary outcome was rate of GI complications after RT. Secondary outcomes were rates of GU incontinence, GU nonincontinence, and erectile dysfunction (ED). Baseline characteristics obtained from the SEER-Medicare database were race, marital status, education level, income, population density of place of residence, region of place of residence, year of diagnosis, pathologic stage, Gleason score, pathologic margin status, age at diagnosis, comorbidities, use of androgen deprivation therapy (ADT), and surgical technique (minimally invasive or open retropubic RP). RT dose data or other technical details are not available in the SEER-Medicare database.

Statistical analysis
--------------------

Baseline characteristics between the IMRT and CRT groups were compared using the chi-square test. A propensity score was calculated for each person using logistic regression to model the probability of treatment. The following variables were included in the propensity score model: race, hispanic origin, marital status, census-tract% high school completion, census-tract median income, population density, SEER region, year of diagnosis, pT stage, Gleason score, margin status, age at diagnosis, comorbidity score, ADT receipt, and surgery type. A propensity score weight was calculated as the inverse predicted probability of being in one\'s treatment group; this weight was then adjusted by the relative sample size of each treatment group. First complication events (based on either procedure or diagnosis code) were reported in events/100 person years and adjustment for potential confounders was performed by propensity score weighting [@b20]. 95% confidence intervals of adjusted rate ratios were calculated by weighted Poisson regression.

Multivariate Cox proportional hazards models of time to first complication (based on procedure codes) were performed for each class of complications. Covariates forced into all models were pathologic T stage (T2, T3a, T3b), Gleason score (≤7, 8+), surgical margins (involved, not involved), age at diagnosis (66--69, 70--74, 75--79, 80+), surgery (open vs. minimally invasive), and ADT use (yes, no), and year of diagnosis (1995--1999, 2000--2004, 2005--2007). The remaining variables from Table[1](#tbl1){ref-type="table"} were considered for multivariable models if they had a level of significance \<0.3 on univariable analysis. The covariate with the largest *P* value was then removed from the model so long as the parameter estimate of treatment effect was not changed by more than 20%. This process was repeated until all covariates had a *P* value of less than 0.1. There was one exception to the 20% change rule utilized in the urinary-nonincontinence model. In this model, several removed covariates impacted the very small treatment effects by \>20%; however, the resulting estimates of difference between RT types were still near zero. Thus, the removed covariates were left out of the final models presented in [Tables 3](#tbl3){ref-type="table"}--[6](#tbl6){ref-type="table"}. Hazard ratios were calculated with 95% confidence intervals and *P* values were considered significant if \<0.05. All Cox models were weighted by the adjusted propensity.

###### 

Baseline characteristics of the CRT and IMRT cohorts.

                                              CRT (*n* = 1052)   IMRT[1](#tf1-1){ref-type="table-fn"} (*n* = 634)   *P*-value (*χ*^2^)
  ------------------------------------------- ------------------ -------------------------------------------------- --------------------
  *Demographic factors*                                                                                             
  Race                                                                                                              
   White                                      940 (89.35)        566 (89.27)                                        0.882
   Black                                      57 (5.42)          32 (5.05)                                          
   Asian/Pacific Islander/other               55 (5.23)          36 (5.68)                                          
  Hispanic                                                                                                          
   Non-Hispanic                               1000 (95.06)       589 (92.90)                                        0.066
   Hispanic                                   52 (4.94)          45 (7.10)                                          
  Marital status                                                                                                    
   Not married                                136 (12.93)        79 (12.46)                                         0.958
   Married                                    892 (84.79)        540 (85.17)                                        
   Unknown                                    24 (2.28)          15 (2.37)                                          
  Education[2](#tf1-2){ref-type="table-fn"}                                                                         
   \<75%                                      153 (14.54)        120 (18.93)                                        0.028
   75--84.99%                                 242 (23.00)        117 (18.45)                                        
   85--89.99%                                 213 (20.25)        120 (18.93)                                        
   90%+                                       444 (42.21)        277 (43.69)                                        
  Income[2](#tf1-2){ref-type="table-fn"}                                                                            
   \<35K                                      188 (17.87)        119 (18.77)                                        0.027
   35--44K                                    241 (22.91)        115 (18.14)                                        
   45--59K                                    284 (27.00)        158 (24.92)                                        
   60K+                                       339 (32.22)        242 (38.17)                                        
  Population density                                                                                                
   Urban                                      1029 (97.81)       626 (98.74)                                        0.171
   Rural                                      23 (2.19)          8 (1.26)                                           
  Region                                                                                                            
   West                                       628 (59.70)        419 (66.09)                                        \<0.001
   Midwest                                    223 (21.20)        56 (8.83)                                          
   Northeast                                  90 (8.56)          84 (13.25)                                         
   South                                      111 (10.55)        75 (11.83)                                         
  Year of diagnosis                                                                                                 
   1995--1999                                 434 (41.25)        30 (4.73)                                          \<0.001
   2000--2004                                 522 (49.62)        260 (41.01)                                        
   2005--2007                                 96 (9.13)          344 (54.26)                                        
  *Tumor-related factors*                                                                                           
  pT                                                                                                                
   T2                                         230 (21.86)        156 (24.61)                                        0.426
   T3a                                        550 (52.28)        318 (50.16)                                        
   T3b                                        272 (25.86)        160 (25.24)                                        
  Gleason score                                                                                                     
   ≤7                                         541 (51.43)        346 (54.57)                                        0.210
   8+                                         511 (48.57)        288 (45.43)                                        
  Margins                                                                                                           
   Uninvolved                                 576 (54.75)        310 (48.90)                                        0.020
   Involved                                   476 (45.25)        324 (51.10)                                        
  Age at diagnosis                                                                                                  
   66--69                                     594 (56.46)        367 (57.89)                                        0.713
   70--74                                     375 (35.65)        221 (34.86)                                        
   75--79                                     78 (7.41)          41 (6.47)                                          
   80+                                        5 (0.48)           5 (0.79)                                           
  Comorbidity                                                                                                       
   0                                          697 (66.25)        411 (64.83)                                        0.746
   1                                          253 (24.05)        163 (25.71)                                        
   2+                                         102 (9.70)         60 (9.46)                                          
  *Treatment factors*                                                                                               
  ADT                                                                                                               
   No                                         470 (44.68)        270 (42.59)                                        0.402
   Yes                                        582 (55.32)        364 (57.41)                                        
  Surgery                                                                                                           
   ORP                                        1017 (96.67)       480 (75.71)                                        \<0.001
   MIRP                                       35 (3.33)          154 (24.29)                                        

CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ADT, androgen deprivation therapy; ORP, open radical prostatectomy; MIRP, minimally invasive radical prostatectomy.

Those with both IMRT and CRT (*n* = 215) are considered IMRT.

Census level variables.

Results
=======

Baseline patient characteristics
--------------------------------

Overall, 1686 patients were identified who met the inclusion criteria, including 1052 who were treated with CRT and 634 were treated with IMRT. The median follow up was 5.7 years for the CRT group and 2 years for IMRT group. The median time to post-RP RT was 7.5 months for the CRT group and 10.2 months for the IMRT group. The IMRT and CRT groups differed according to region, year of diagnosis, education level, and income level (Table [1](#tbl1){ref-type="table"}). There was a trend toward increased utilization of IMRT over time. Patients treated with IMRT were also more likely both to have positive surgical margins and to have received a minimally invasive (vs. open) RP (Table [1](#tbl1){ref-type="table"}).

Adjusted complication rates
---------------------------

Rates of first complication, according to class of complication, were adjusted based upon propensity score using Table [1](#tbl1){ref-type="table"} variables, and are presented in units of events per 100 person years with rate ratios and 95% confidence intervals (Table [2](#tbl2){ref-type="table"}). Additional data regarding time interval between RT and complications are presented in Table S2. Patients treated with IMRT had a lower rate of GI complications but a higher rate of GU incontinence complications based on procedure codes when compared to the CRT group. There was no difference in the rate of ED or GU nonincontinence complications between the treatment groups (Table [2](#tbl2){ref-type="table"}). Unadjusted rates of first complications are presented in Table S3.

###### 

Propensity score-adjusted complication rates, defined by procedure and diagnosis codes, listed according to class of complications.

  Complications by class    CRT (*n* = 1052)   IMRT (*n* = 634)   IMRT vs. CRT comparison
  ------------------------- ------------------ ------------------ -------------------------
  Erectile dysfunction                                            
   Procedure                0.82               0.50               0.61 (0.29, 1.29)
   Diagnosis                6.71               7.24               1.08 (0.86, 1.35)
  Gastrointestinal                                                
   Procedure                13.16              8.80               0.67 (0.55, 0.81)
   Diagnosis                11.05              9.93               0.90 (0.74, 1.09)
  Urinary--incontinence                                           
   Procedure                4.46               8.06               1.81 (1.44, 2.27)
   Diagnosis                7.22               9.46               1.31 (1.07, 1.60)
  Urinary-nonincontinence                                         
   Procedure                3.21               2.86               0.89 (0.64, 1.24)
   Diagnosis                6.45               7.38               1.14 (0.92, 1.43)

CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy.

Multivariable analysis of time to first complication
----------------------------------------------------

Cox proportional hazards models of the time to first GI, urinary-incontinence, urinary-nonincontinence, and ED complications (procedures) are presented in [Tables 3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}, [5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}, respectively. On multivariable analysis, use of IMRT was associated with a lower rate of GI, and higher rate of urinary-incontinence procedure events compared to CRT.

###### 

Propensity-score-weighted cox proportional hazards model: time to first GI complication (using procedure codes).

  Parameter                    Hazard ratio   95% Confidence interval   *P*       Overall *P*
  ---------------------------- -------------- ------------------------- --------- -------------
  RT type                                                                         
   IMRT vs. CRT                0.68           (0.56, 0.83)              \<0.001   \<0.001
  pT stage                                                                        
   T3a vs. T2                  0.96           (0.75, 1.22)              0.711     0.744
   T3b vs. T2                  0.88           (0.63, 1.24)              0.463     
  Gleason                                                                         
   8+ vs. \<7                  1.04           (0.88, 1.23)              0.657     0.657
  Margins                                                                         
   Involved vs. uninvolved     1.05           (0.83, 1.32)              0.712     0.712
  Age at diagnosis                                                                
   70--74 vs. 66--69           0.99           (0.83, 1.18)              0.894     0.894
   75--79 vs. 66--69           0.89           (0.62, 1.28)              0.531     
   80+ vs. 66--69              0.75           (0.24, 2.39)              0.625     
  Surgery                                                                         
   MIRP vs. ORP                0.94           (0.63, 1.43)              0.786     0.786
  ADT                                                                             
   Yes vs. no                  1.03           (0.86, 1.22)              0.766     0.766
  Year of diagnosis                                                               
   2000--2004 vs. 1995--1999   1.23           (1.01, 1.49)              0.042     0.020
   2005--2007 vs. 1995--1999   0.86           (0.61, 1.21)              0.395     
  Race                                                                            
   Black vs. white             1.48           (1.07, 2.06)              0.019     0.006
   Other vs. white             1.53           (1.07, 2.18)              0.019     
  Hispanic origin                                                                 
   Yes vs. no                  0.59           (0.37, 0.93)              0.024     0.024
  Median household income                                                         
   \<35K vs. 35--44K           0.92           (0.69, 1.22)              0.544     0.015
   45--59K vs. 35--44K         1.19           (0.93, 1.52)              0.165     
   60K+ vs. 35--44K            1.35           (1.07, 1.70)              0.011     
  Region                                                                          
   Midwest vs. west            1.27           (1.00, 1.60)              0.047     0.049
   Northeast vs. west          1.26           (0.95, 1.66)              0.106     
   South vs. west              1.35           (1.03, 1.77)              0.031     

GI, gastrointestinal; RT, radiation therapy; CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ADT, androgen deprivation therapy; ORP, open radical prostatectomy; MIRP, minimally invasive radical prostatectomy.

Proportionality assumption test, *P* = 0.077.

###### 

Propensity-score-weighted cox proportional hazards model: time to first UI complication (using procedure codes).

  Parameter                    Hazard ratio   95% Confidence interval   *P*       Overall *P*
  ---------------------------- -------------- ------------------------- --------- -------------
  RT type                                                                         
   IMRT vs CRT                 1.90           (1.49, 2.42)              \<0.001   \<0.001
  pT stage                                                                        
   T3a vs. T2                  0.71           (0.51, 0.99)              0.044     0.074
   T3b vs. T2                  0.60           (0.38, 0.94)              0.028     
  Gleason                                                                         
   8+ vs. \<7                  0.89           (0.71, 1.12)              0.321     0.321
  Margins                                                                         
   Involved vs. uninvolved     0.85           (0.62, 1.17)              0.316     0.316
  Age at diagnosis                                                                
   70--74 vs. 66--69           1.48           (1.17, 1.87)              0.001     0.007
   75--79 vs. 66--69           1.60           (1.03, 2.48)              0.038     
   80+ vs. 66--69              1.07           (0.23, 4.91)              0.928     
  Surgery                                                                         
   MIRP vs. ORP                0.74           (0.42, 1.32)              0.312     0.312
  ADT                                                                             
   Yes vs. no                  1.04           (0.83, 1.31)              0.739     0.739
  Year of diagnosis                                                               
   2000--2004 vs. 1995--1999   0.97           (0.73, 1.27)              0.809     0.762
   2005--2007 vs. 1995--1999   1.11           (0.73, 1.70)              0.615     
  Hispanic origin                                                                 
   Yes vs. no                  1.75           (1.15, 2.67)              0.009     0.009
  Region                                                                          
   Midwest vs. west            0.84           (0.60, 1.19)              0.327     0.012
   Northeast vs. west          1.11           (0.75, 1.64)              0.590     
   South vs. west              1.64           (1.18, 2.29)              0.004     

UI, urinary incontinence; RT, radiation therapy; CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ADT, androgen deprivation therapy; ORP, open radical prostatectomy; MIRP, minimally invasive radical prostatectomy.

Proportionality assumption test, *P* = 0.079.

###### 

Propensity-score-weighted cox proportional hazards model: time to first UN complication (using procedure codes).

  Parameter                      Hazard ratio   95% Confidence interval   *P*     Overall *P*
  ------------------------------ -------------- ------------------------- ------- -------------
  RT type                                                                         
   IMRT vs CRT                   1.02           (0.71, 1.48)              0.912   0.912
  pT stage                                                                        
   T3a vs. T2                    1.16           (0.75, 1.81)              0.502   0.669
   T3b vs. T2                    1.31           (0.73, 2.36)              0.370   
  Gleason                                                                         
   8+ vs. \<7                    0.81           (0.61, 1.09)              0.172   0.172
  Margins                                                                         
   Involved vs. uninvolved       0.96           (0.64, 1.43)              0.828   0.828
  Age at diagnosis                                                                
   70--74 vs. 66--69             1.43           (1.06, 1.93)              0.021   0.074
   75--79 vs. 66--69             1.36           (0.78, 2.38)              0.283   
   80+ vs. 66--69                2.77           (0.68, 11.23)             0.154   
  Surgery                                                                         
   MIRP vs. ORP                  0.48           (0.20, 1.14)              0.095   0.095
  ADT                                                                             
   Yes vs. no                    1.43           (1.05, 1.94)              0.022   0.022
  Year of diagnosis                                                               
   2000--2004 vs. 1995--1999     0.89           (0.62, 1.27)              0.523   0.814
   2005--2007 vs. 1995--1999     0.90           (0.50, 1.61)              0.714   
  Marital status                                                                  
   Not married vs. married       1.50           (1.02, 2.21)              0.038   0.099
   Unknown vs. married           0.75           (0.22, 2.54)              0.640   
  Median household income                                                         
   \<35K vs. 35--44K             1.44           (0.89, 2.31)              0.137   0.067
   45--59K vs. 35--44K           1.14           (0.72, 1.81)              0.584   
   60K+ vs. 35--44K              1.65           (1.08, 2.51)              0.019   
  Region                                                                          
   Midwest vs. west              0.60           (0.37, 0.97)              0.036   0.008
   Northeast vs. west            0.71           (0.42, 1.21)              0.209   
   South vs. west                1.52           (0.98, 2.34)              0.059   
  Time from RP to RT                                                              
   90--179 days vs. \<90 days    1.07           (0.70, 1.62)              0.761   0.087
   180--359 days vs. \<90 days   0.97           (0.61, 1.55)              0.913   
   360--899 days vs. \<90 days   0.66           (0.40, 1.08)              0.097   
   900+ days vs. \<90 days       0.60           (0.35, 1.02)              0.059   

UN, urinary non-incontinence; RT, radiation therapy; CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ADT, androgen deprivation therapy; RP, radical prostatectomy; ORP, open radical prostatectomy; MIRP, minimally invasive radical prostatectomy.

Proportionality assumption test, *P* = 0.190.

###### 

Propensity-score-weighted cox proportional hazards model: time to first ED complication (using procedure codes).

  Parameter                      Hazard ratio   95% Confidence interval   *P*     Overall *P*
  ------------------------------ -------------- ------------------------- ------- -------------
  RT type                                                                         
   IMRT vs CRT                   0.71           (0.32, 1.57)              0.395   0.395
  pT stage                                                                        
   T3a vs. T2                    2.36           (0.89, 6.22)              0.084   0.060
   T3b vs. T2                    4.63           (1.30, 16.53)             0.018   
  Gleason                                                                         
   8+ vs. \<7                    1.15           (0.63, 2.10)              0.639   0.639
  Margins                                                                         
   Involved vs. uninvolved       1.35           (0.60, 3.06)              0.468   0.468
  Age at diagnosis                                                                
   70--74 vs. 66--69             0.65           (0.35, 1.22)              0.179   0.196
   75+ vs. 66--69                0.32           (0.06, 1.67)              0.177   
  Surgery                                                                         
   MIRP vs. ORP                  3.74           (1.59, 8.80)              0.003   0.003
  ADT                                                                             
   Yes vs. no                    0.58           (0.32, 1.06)              0.076   0.076
  Year of diagnosis                                                               
   2000--2004 vs. 1995--1999     0.86           (0.41, 1.83)              0.697   0.898
   2005--2007 vs. 1995--1999     0.80           (0.29, 2.21)              0.665   
  Hispanic origin                                                                 
   Yes vs. no                    3.00           (1.19, 7.59)              0.020   0.020
  At least HS education (zip)                                                     
   75--85% vs. \<75%             1.58           (0.61, 4.13)              0.347   0.076
   85--90% vs. \<75%             2.16           (0.83, 5.64)              0.117   
   90%+ vs. \<75%                0.86           (0.33, 2.28)              0.764   
  Time from RP to RT                                                              
   90--179 days vs. \<90 days    3.33           (1.30, 8.57)              0.012   0.006
   180--359 days vs. \<90 days   2.21           (0.79, 6.17)              0.130   
   360--899 days vs. \<90 days   1.22           (0.38, 3.93)              0.744   
   900+ days vs. \<90 days       0.12           (0.01, 1.57)              0.106   

ED, erectile dysfunction; RT, radiation therapy; CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ADT, androgen deprivation therapy; RP, radical prostatectomy; ORP, open radical prostatectomy; MIRP, minimally invasive radical prostatectomy; HS, high school.

Proportionality assumption test, *P* = 0.674.

Discussion
==========

In this population-based cohort study, the use of IMRT for postprostatectomy RT was associated with a decreased rate of GI complications when compared to CRT. The rate of urinary-incontinence complications was higher for the IMRT group, and there was no difference between the treatment groups in the two other classes of complications evaluated: urinary-nonincontinence and ED. The delivery of RT within 3 months after RP was not associated with increased risk of complications in this cohort, which has potential implications for clinical decisions regarding early versus delayed RT after RP.

The observed decreased risk of GI complications associated with the use of IMRT is not unexpected, as dosimetric studies have demonstrated that IMRT decreases the volume of rectum receiving high doses [@b10],[@b11]. This is consistent with findings from population-based comparative effectiveness analyses in intact prostate gland RT where IMRT resulted in lower rates of GI toxicity [@b15],[@b16]. Additionally, single institution retrospective data of salvage RT suggested that IMRT was associated with a decreased rate of grade 2+ GI toxicity at 5 years (1.9% vs. 10.2%) [@b21].

Perhaps most notably, however, our finding in this study concerning GI complications is in disagreement with the findings of Goldin and colleagues, who identified no differences in GI, GU, or sexual complications in their comparison of IMRT and CRT in a similar cohort of prostate cancer patients from the SEER-Medicare database [@b22]. This study cohort differs from the Goldin et al. study by including subjects from a longer time period, including RT delivered at any length of time after RP (including more than 3 years after RP), and by restricting the cohort to patients with adverse pathological features (extracapsular extension, seminal vesical invasion, and/or positive surgical margins) to evaluate only those individuals eligible for ART. This study focused specifically on the cohort of patients who would be considered for ART, as the risk of complications has been shown to influence treatment decisions for such patients [@b6], and additional data could lead to better-informed choices. Both studies include propensity score adjustment, but with slightly different empiric assumptions in the statistical methodology. The difference in results between these two studies demonstrates the potential influence of investigators\' methods in observational cohort studies and emphasizes a need for replicative and complementary studies in scientific inquiry.

In this study, IMRT was associated with a higher rate of urinary-incontinence complications, but not other urinary complications, compared to CRT. The reason for this finding is not clear, but a variety of factors could contribute to this finding. It is possible that trends toward higher RT doses over time have paralleled the observed trend toward increased IMRT utilization during the study period (from 33% in 2000--2004 to 78% in 2005--2007). This is a reasonable expectation based upon the publication of evidence during this time period that suggested a benefit to higher RT doses for post-RP RT [@b23],[@b24]. However, data regarding radiation dose and technical specifications are not available in the SEER-Medicare database, so the influence of dose cannot be evaluated in this study. In addition, detailed dosimetric characteristics of the IMRT and CRT plans and information on the definition of target volumes are not available. Consensus guidelines [@b9] for definition of the prostatic fossa were not published until after the designated study period, potentially leading to great variability in the definition of target volumes in this cohort. The volume of bladder receiving very high RT doses is predictive of GU toxicity [@b25],[@b26], and IMRT can result in increased dose heterogeneity within the irradiated volume and an increased maximum bladder dose compared to 3D [@b10],[@b11]. It is not clear how variation in dosimetry could influence the observed results. One limitation of this analysis is that it is not possible to determine the etiology of urinary incontinence due to the combination of RP and RT, both of which could contribute to this complication. Baseline incontinence after RP could either improve or resolve prior to RT, thus the presence of baseline incontinence could not be adjusted for in our analysis. Although an explanation is not immediately available, the observed increase in urinary incontinence with IMRT, compared to CRT, after RP suggests a need for further evaluation in future studies.

Although no difference was observed between IMRT and CRT for procedures for ED, parameters that were associated with increased risk of ED included minimally invasive RP (vs. open RP), Hispanic origin, and time interval from RP to RT. That RT delivered within 90 days of RP, compared to more later time intervals, was associated with decreased risk of ED procedures is a surprising observation, and contradicts the clinical practice of delaying RT as long as possible to reduce risk of ED after RP [@b5]. Although provocative, this finding should be interpreted with caution, as data are not available regarding baseline sexual function and patient motivation for interventions, which may influence whether procedures are performed [@b27].

The strengths of this study include the large size of the cohort and the evaluation of outcomes in a real-world, noncontrolled setting. However, there are limitations related to the use of the SEER-Medicare data to evaluate outcomes after RT in this setting [@b28],[@b29]. For instance, data are not available regarding several important elements that could potentially affect the risk of complications, including RT dose, doses delivered to bladder and rectum, the use of image guided radiation therapy (IGRT), and other technical details. There is no information for the fields used for RT, so it is possible that the RT delivered was in fact not to the prostate fossa, but to another body site such as bone in the setting of metastatic disease. In the current analysis, we addressed this issue by excluding those subjects who received RT for a diagnosis of bone metastasis in the absence of a prostate cancer code. However, it is possible that some subjects in our cohort received RT for bone metastasis rather than for the prostate bed. The presence of the bone metastasis code (198.5) was rare in our cohort, recorded for only seven subjects at the start of their RT. In the definitive treatment of patients with intact prostate glands, there are data to suggest that image-guidance approaches during RT delivery are associated with a decreased rate of grade 2+ GU toxicity at 2 years (10% vs. 20%), when compared to treatment without image-guidance [@b30]. Localization of the target volume on pretreatment imaging allows for decreased planning target volume margins and potentially improved avoidance of critical structures over the course of treatment. Furthermore, the available details are limited regarding post-RT complications, so it is possible that the risk estimates can over-or underestimate the occurrence of events attributable to RT. Additionally, there is a difference in the duration of follow-up between the two study groups, and the observed complication rates could change with increased follow-up in the IMRT group. Therefore, it is possible that this study overestimates the comparative benefits of IMRT (vs. CRT).

A trend toward increased use of IMRT was observed during the study period, with 78% of subjects diagnosed between 2005 and 2007 receiving IMRT. This is similar to the rate reported recently by Goldin and colleagues in their analysis of SEER-Medicare data [@b22], as well as to the findings of a national survey of radiation oncologists regarding their practice policies for post-RP RT [@b6]. It is critical that the potential advantages of IMRT be weighed carefully in light of the added costs of advanced technologies [@b12]. In light of the mixed results observed with IMRT in this study, and the lack of differences observed by Goldin et al. in their analysis [@b22], additional research should be pursued to more thoroughly evaluate the role of IMRT after RP and to determine whether IMRT offers value in this setting.

Conclusions
===========

The use of IMRT after prostatectomy was associated with decreased risk of GI complications, when compared to CRT, but an increased risk of urinary-incontinence complications. Although this observational cohort study provides some insights into outcomes after post-RP RT, additional studies are needed to evaluate the comparative effectiveness and cost-effectiveness of advanced RT technologies in this context.
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###### 

Cohort selection diagram for prostate cancer patients in SEER-Medicare database who received IMRT or CRT after prostatectomy. The analysis compared outcomes after IMRT (*n* = 634) and CRT (*n* = 1052). RP, radical prostatectomy; RT, radiation therapy; CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; Dx, diagnosis.

###### 

**Table S1** Diagnosis and procedure codes used to define treatment type and complications. ICD-9, International Classification of Diseases version 9; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedural Coding System; MIRP, minimally invasive radical prostatectomy; ORP, open radical prostatectomy.

**Table S2**. Time to first complication, by type, for subjects receiving CRT or IMRT. Time is defined from the start of radiation therapy.

**Table S3.** Complication rates without adjustment by propensity score, defined by procedure and diagnosis codes, listed according to class of complications.

[^1]: Presented at the 55th Annual Meeting of the American Society for Radiation Oncology, Atlanta, GA, 22--25 September 2013.
